Side-by-side comparison of AI visibility scores, market position, and capabilities
SHINE Technologies uses fusion neutron technology to produce medical isotopes; received a conditional $263M DOE loan in April 2026 to complete the Chrysalis Mo-99 facility in Janesville, WI; facility 75-80% complete.
SHINE Technologies is a Janesville, Wisconsin-based company that is commercializing fusion technology for practical near-term applications — starting with medical isotope production, nuclear waste characterization, and industrial component inspection. Unlike fusion energy companies pursuing electricity generation as their first market, SHINE has built a phased commercialization strategy: its fusion neutron systems produce the radioisotopes used in medical imaging and cancer treatment today, generating commercial revenue while advancing the underlying fusion technology toward energy applications.
Publicly traded AI precision medicine company (Nasdaq: TEM); $1.27B revenue in 2025 (+83% YoY); $14B+ market cap; genomic profiling, algorithmic diagnostics, and clinical trial matching across oncology, neurology, and cardiology.
Tempus AI is a technology company applying artificial intelligence to advance precision medicine across oncology, neurology, psychiatry, and cardiology. Founded in 2015 by Eric Lefkofsky (co-founder of Groupon) and headquartered in Chicago, Illinois, Tempus built the world's largest library of clinical and molecular data and applies AI to help physicians make more personalized, data-driven treatment decisions. The company's core offerings include genomic profiling (sequencing tumor DNA to identify mutations and actionable targets), algorithmic diagnostic tests (AI-driven companion diagnostics for cancer treatment selection), clinical trial matching (connecting eligible patients to appropriate studies), and data licensing to pharmaceutical and biotech partners for drug discovery and clinical development.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.